Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jisheng Wang has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Sheng Deng

    Department of Andrology, Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital, Beijing, China

    10 shared publications
  • Bin Wang

    Andrology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    8 shared publications
  • Fanchao Meng

    Department of Andrology, Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, China

    6 shared publications
  • Haisong Li

    Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    6 shared publications
  • Junlong Feng

    First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China

    6 shared publications
  • Junlong Feng

    Andrology Department, Beijing Changping District Traditional Chinese Medicine Hospital, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    A Combination of Cuscuta chinensis and Lycium barbarum Ameliorates Spermatogenic Impairment in Mice and Is Associated With Modulation of the miR-21/PTEN/PI3K/AKT/mTOR Signaling Axis

    by Haoran Chang, Junlong Feng, Lixing Lei, Xiangfa Lin, Maoke Chen, Zixiang Gao, Jisheng Wang, Haisong Li

    SC-FL is a traditional Chinese herbal formula that has been used for kidney tonification and the clinical treatment of oligospermia and asthenospermia. This medicinal compound comprises dodder seed ( Cuscuta chinensis Lam .) and wolfberry fruit ( Lycium barbarum L .). However, the precise mechanisms of SC-FL remain undetermined. Therefore, this study aimed to identify potential therapeutic targets of SC-FL in oligoasthenozoospermia and validate these targets in vivo . To establish a spermatogenic dysfunction model, male BALB/c mice were administered glucosides of Tripterygium wilfordii Hook. f. (GTW) and then treated with SC-FL. Furthermore, the expression of microRNA-21 (miR-21), key PI3K/AKT/mTOR signaling pathway-related proteins and mRNAs, as well as molecular markers of cell proliferation and apoptosis, was evaluated. The results indicated that the mouse body weight did not significantly differ across SC-FL-treated groups compared to the GTW group (non-treated model group); however, the high-dose SC-FL mice showed significantly higher testicular weight ( p < 0.05 ). Both medium- and high-dose SC-FL mice showed significantly increased sperm concentration and motility relative to the GTW group ( p < 0.01 ). Histological analysis by hematoxylin and eosin staining revealed that SC-FL treatment alleviated GTW-induced testicular tissue damage and preserved testicular structure. SC-FL treatment reduced serum IL-6 and TNF-α levels and decreased PTEN mRNA and protein expression. It also increased miR-21, PI3K, AKT, and mTOR mRNA expression and increased the phosphorylated protein levels of PI3K, AKT, and mTOR, whereas total PI3K, AKT, and mTOR protein abundance remained relatively unchanged. In conclusion, SC-FL increased sperm concentration and motility and reduced serum inflammatory cytokine levels in mice. These beneficial effects were accompanied by increased miR-21 expression, decreased PTEN expression, and increased phosphorylation of PI3K, AKT, and mTOR. These findings indicate an association between the protective effects of SC-FL and alterations in the miR-21/PTEN/PI3K/AKT/mTOR signaling axis, but do not establish causal mediation by this pathway.

  • Open Access

    CP1Hao Decoction Alleviates Chronic Prostatitis by Modulating Arachidonic Acid Metabolism: A Multi-Omics Analysis

    by Li-Xing Lei, Hao-Ran Chang, Jun-Long Feng, Yu Xia, Hui Chen, Xiang-Fa Lin, Ke-Cheng Li, Long-Ji Sun, Lu Wang, Ji-Sheng Wang

    CP1Hao Decoction (CP1HD) is a traditional Chinese herbal prescription used to treat chronic prostatitis, but the therapeutic effects and underlying mechanisms of CP1HD, particularly those involving arachidonic acid metabolism and gut microbiota, remain unclear. This study evaluated the pharmacological efficacy of CP1HD in a carrageenan-induced rat model of prostatitis and explored its potential targets and pathways through integrated transcriptomics, 16S rRNA sequencing, and metabolomics analyses. CP1HD treatment significantly alleviated prostate histopathological damage, reduced the prostate index, and suppressed inflammatory responses. ELISA results showed that CP1HD markedly decreased the levels of TNF-α, IL-6, PGE2, LTB4, and COX-2, while regulating EETs levels, and inhibited M1 macrophage polarization and neutrophil infiltration while promoting M2 polarization. Transcriptomic analysis revealed that CP1HD reversed differentially expressed genes associated with inflammation and arachidonic acid metabolism, which was further confirmed by Western blot analysis of cPLA2, LTA4H, and sEH. In addition, CP1HD modulated gut microbiota composition by restoring the relative abundance of Bacteroides , Alistipes , and the Eubacterium_siraeum group . Metabolomic profiling demonstrated that CP1HD regulated arachidonic acid metabolism and related lipid mediators, with notable effects on phosphatidylethanolamine metabolism and fatty acid β-oxidation. Overall, CP1HD ameliorates prostatitis by reducing inflammation and prostate injury while modulating arachidonic acid metabolism, gut microbiota, and associated metabolic pathways.


  • Open Access

    Plasma fatty acid composition modifies the cardiovascular risk of long-term PM2.5 exposure: a prospective cohort study of 428,048 participants

    by Cong Zhao, Leying Zhao, Yihan Zhang, Lu Wang, Jinghua Yang, Ang Gao, Jisheng Wang, Xian Wang

    This study aimed to investigate whether plasma fatty acid composition is associated with incident atherosclerotic cardiovascular disease (ASCVD) and whethe


  • Open Access

    The Guangsi Yulin Decoction Inhibits Oxidative Stress and Inflammation-Induced Spermatogenesis Dysfunction via the PTEN / PI3K / AKT / FoxO1 Pathway

    by Xiangfa Lin, Junlong Feng, Haoran Chang, Hui Chen, Nianwen Huang, Kecheng Li, Maoke Chen, Haisong Li, Lu Wang, Jisheng Wang

    Guangsi Yulin Decoction (GSYLD) is a traditional Chinese medicine (TCM) formula with therapeutic efficacy against spermatogenesis dysfunction. However, the underlying mechanism of the alleviation remains unclear. To investigate the effects of GSYLD on Tripterygium wilfordii polyglycolide (GTW)-induced spermatogenesis dysfunction in mice and to explore associated mechanisms, particularly its role in oxidative stress and inflammation. A total of 60 (7–8-week-old) BALB/c mice were grouped into control (NC), model (GTW), low-dose GSYLD (GSYLD-L, 0.27 g/kg/d), high-dose GSYLD (GSYLD-H, 1.08 g/kg/d), and PTEN inhibitor (1.08 g/kg/d GSYLD-H + 0.3 mg/kg PTEN inhibitor). After eight weeks, the model was validated, and semen quality was evaluated by assessing sperm vitality and concentration. Testicular tissues were analyzed by H&E staining, while Western blotting and RT-qPCR (Reverse Transcription Quantitative PCR) were used to assess the therapeutic efficacy of the GSYLD. In comparison to the GTW group, the GSYLD-H group showed a significant improvement in sperm vitality and concentration ( p < .01). GSYLD upregulated PI3K , AKT , and FoxO1 , while downregulating PTEN mRNA expression ( p < .001). A parallel recovery was observed at the protein level. Specifically, the GSYLD-H group exhibited a significant amelioration of oxidative stress and inflammation, marked by reduced MDA, TNF-α, and IL-6 levels ( p < .01) and enhanced SOD activity ( p < .001) relative to the GTW group. GSYLD alleviated GTW-induced spermatogenesis dysfunction, potentially through PTEN / PI3K / AKT / FoxO1 -mediated regulation of oxidative stress and inflammation.

  • Shuangdong Capsule Activates Insulin Signal Pathway to Improve Urinary Tract Infection in Diabetic Rats

    by Cong Zhao, Bin Wang, Qi-Xiang Mu, Jun Wu, Zhen-Han Cheng, Qing Liu, Hai-Song Li, Ji-Sheng Wang

    Background and Aim: Diabetes and Urinary Tract Infections (UTIs) are both common and serious health problems. Shuangdong capsule, a Chinese patent medicine, has been used to treat these conditions. This study assesses its efficacy and mechanism in treating diabetes combined with UTIs. Methods: We induced diabetes in rats using streptozotocin and UTIs with Escherichia coli, dividing the rats into five groups: control, model, levofloxacin, Shuangdong capsule, and levofloxacin + Shuangdong capsule. After two weeks, we measured blood glucose, insulin, infection indicators, and bladder histology. We also detected the expression of insulin receptor substrate 1 (IRS1)-phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt)-C-X-C motif chemokine ligand 2 (CXCL2) signaling pathway by Western Blot and the myeloperoxidase (MPO) levels by Enzyme-Linked Immunosorbent Assay (ELISA). Additionally, we conducted a Mendelian randomization study using genetic variants of the insulin receptor to assess its causal effect on UTI risk. Results: Shuangdong capsule improved bladder pathology and infection indicators, similar to levofloxacin. It did not affect blood glucose or insulin levels. Moreover, it reversed the suppression of the IRS1-PI3K-Akt-CXCL2 pathway and MPO levels caused by UTI in diabetic rats. The Mendelian randomization study showed that increased insulin receptor expression reduced UTI risk, which was consistent with the results of the animal experiments. Conclusion: The Shuangdong capsule was effective in treating diabetes with UTIs. It may function by activating the IRS1-PI3K-Akt signaling pathway, thereby increasing CXCL2 and MPO levels, enhancing innate immunity, and promoting bacterial clearance. The Mendelian randomization study provided further evidence supporting the causal role of the insulin receptor in UTI prevention.


  • Open Access

    Analysis of Current Status of Clinical Trial Registrations in Andrological Diseases: Insights from ClinicalTrials.gov and ICTRP Databases

    by Li-Xing Lei, Ke-Cheng Li, Wen-Hao Yu, Jun-Long Feng, Hua-Nan Zhang, Mao-Ke Chen, Wen-Xuan Dong, Ji-Xuan Chen, Jie Li, Ji-Sheng Wang, et al.

    This study aims to analyze the registration information and outcome transparency for five common andrological diseases, as well as the factors influencing result availability. A comprehensive search was performed on ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) to retrieve all clinical trial registration data related to the five defined andrological diseases from the inception of these databases up to September 1, 2024. The search extracted key trial details, including status, type, intervention, and result availability. Of 8,132 trials retrieved, 642 were analyzed. Among these, 259 trials (40.34%) reported results via ClinicalTrials.gov, ICTRP, or publications, while 113 trials (17.60%) made results publicly available on ClinicalTrials.gov or ICTRP. Among the five andrological diseases, male infertility had the highest rate of result availability (37/74, 50%), whereas benign prostatic hyperplasia exhibited the lowest (71/190, 37.37%). No significant differences were found across diseases (χ 2 = 3.722, df = 4, p = .435). Factors such as study status, blinding, interventions, center type, location, and duration significantly influenced result availability, whereas study type, stage, funding, outcome indicators, and sample size did not. Clinical trials on andrological conditions show major gaps in registration and result disclosure, with low reporting rates and prevalent non-reporting and selective reporting. Developed countries dominate trial registration and result disclosure while developing countries have limited participation. Trial characteristics also influence result disclosure rates. These challenges compromise the integrity and credibility of research data, impede clinical practice, and hinder the progress of medical research. Measures are needed to improve transparency, reduce selective reporting, and enhance the rigor and credibility of andrology research.


  • Open Access

    Hirudin-Based Treatment of Diabetes-Induced Erectile Dysfunction Through Inhibition of the HIF-1α to Regulate RhoA/ROCK Signaling Pathway: An In Vivo Animal Experiment

    by Longji Sun, Nianwen Huang, Chao Yang, Junlong Feng, Hui Chen, Weidong Feng, Zixiang Gao, Bin Wang, Jisheng Wang

    Diabetes-induced erectile dysfunction (DIED) is a type of refractory erectile dysfunction which can be clinically treated using the traditional Chinese medicine leech whose main ingredient is hirudin. Oxidative stress can damage vascular endothelial cells, affect blood circulation, and induce fibrosis of smooth muscle cells. This study assessed the efficacy of hirudin in treating DIED before exploring its potential mechanism of action. DIED was induced in rats using streptozotocin, while experimental apomorphine was used to screen for erectile dysfunction models. The rats were then divided into four groups: a blank control group (NC group), a model group (M group), a hirudin group (H group), and an inhibitor group (YC group). After 2 weeks, the serum levels of malondialdehyde (MDA), superoxide dismutase (SOD), and nitric oxide (NO) were determined. The histological features and HIF-1α/RhoA/ROCK signaling pathway-related proteins of the penile corpus cavernosum were detected. Erectile function improved in the H and YC groups without significantly affecting body weight and blood glucose levels, with histopathological analysis also showing improvement in penile structure in these groups. In addition, the expression of HIF-1α/RhoA/ROCK signaling pathway-related proteins was lower in the penile cavernous tissue of rats in the H and YC groups ( p < .05), with the serum levels of NO and SOD also being higher in these groups ( p < .05). The serum level of MDA decreased in the YC and H groups ( p < .05). In this study, only animal experiments were conducted to investigate the regulation of Rho/ROCK pathway by HIF-1α. Cellular studies of the underlying mechanisms are lacking.


  • Open Access

    Guijiajiao-Lujiaojiao Synergistically Promote Spermatogenesis in Tripterygium Wilfordii Polyglycoside–Induced Oligoasthenozoospermia Rats via PI3K/AKT Signaling Pathway

    by Nianwen Huang, Haisong Li, Longji Sun, Junlong Feng, Zixiang Gao, Zhechao Lin, Yong Yang, Bin Wang, Jisheng Wang

    Guijiajiao-Lujiaojiao (GL) is a combination of Traditional Chinese Medicine (TCM) that can be used to treat oligoasthenozoospermia (OAS). However, its mechanistic role in OAS needs to be better understood and necessitates more studies. This study was planned to investigate GL’s therapeutic effects and its mechanistic role in the tripterygium wilfordii polyglycoside (GTW)-induced OAS rat model. In total, 60 Sprague–Dawley (SD) rats at 8 weeks of age were assigned to six groups: blank (NC), model (GTW), GL low-dose (GL-L, 0.3 g/kg/day), GL medium-dose (GL-M, 0.6 g/kg/day), GL high-dose (GL-H, 1.2 g/kg/day), and GL high-dose + PI3K inhibitor LY294002 (GL-H 1.2 g/kg/day + LY 1.2 mg/kg/day) groups. The model was characterized after 8 weeks to examine sperm concentration and viability, serum hormone levels, testes histopathology, and specific protein markers. The treatment efficacy was evaluated by mRNA and protein expression levels, among other parameters. Compared with the GTW group, the viability and concentration of rat spermatozoa were significantly increased after GL intervention ( p < .01). Meanwhile, the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and T hormones in rats in the GL-M and GL-H groups were significantly higher than those in the GTW group ( p < .05). Furthermore, GL enhanced the proliferation of spermatogenic cells by modulating the PI3K/AKT signaling pathway, increasing and decreasing the levels of Bcl-2 and Bax proteins, respectively. It is concluded that the mechanism by which GL effectively enhanced the spermatogenic function of the GTW-induced OAS model may be attributed to the PI3K/AKT signaling pathway activation and the elevation of serum LH, FSH, and T hormone levels.


  • Open Access

    Bioinformatics Combined With Experimental Modeling to Study the Molecular Mechanism of Xuefu Zhuyu Decoction to Improve Erectile Dysfunction Associated With Asthma in Rats

    by Junlong Feng, Sheng Deng, Xuefeng Gong, Bin Wang, Longji Sun, Huanan Zhang, Zixiang Gao, Hui Chen, Kali Zou, Jiaqi Yang, et al.

    Asthma is associated with chronic systemic inflammation, and inflammatory factors can damage vascular endothelial cells, thus impairing erectile function (ED). Xuefu Zhuyu decoction (XFZYD) can inhibit inflammation and promote angiogenesis, which in turn improves asthma as well as ED, but its exact mechanism of action is not yet clear. This study investigates the mechanism underlying the beneficial effect of XFZYD on asthma-associated ED. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was used to analyze the constituents of XFZYD, and network pharmacology analysis was used to predict the target genes of XFZYD. Sprague–Dawley rats in the asthma model with erectile dysfunction were divided into the model, XFZYD low-, medium-, and high-dose group (3.09, 6.17, and 12.34 g/kg), with drug intervention for 8 weeks. We assessed the interleukin 6 (IL-6), vascular endothelial growth factor A (VEGFA), and tumor necrosis factor (TNF) protein levels in the penile tissue. We discovered that after treatment with XFZYD (3.09, 6.17, and 12.34 g/kg), the number of erections significantly increased (1.17 ± 0.41, 1.50 ± 0.55, and 1.67 ± 0.52), the density of endothelial cells in the corpus cavernosum of the penis increased, the expression level of IL-6 was reduced (7.5%, 21.2%, and 24.4%), the expression level of VEGFA was reduced (7.8%, 25%, and 28.4%), and the expression level of TNF was reduced (13.5%, 30.6%, and 32.4%). The in vivo experiments indicate that XFZYD may improve ED in asthma model rats by inhibiting inflammation and reducing vascular permeability. This study provides new insights into the mechanism of action of XFZYD in the treatment of asthma leading to ED.


  • Open Access

    Mechanisms of Xuefu Zhuyu Tang in the Treatment of Diabetic Erectile Dysfunction in Rats Through the Regulation of Vascular Endothelial Function by CaSR/PLC/PKC and MEK/ERK/RSK Pathways

    by Xiao Li, Mingzhao Zhang, Junlong Feng, Jisheng Wang, Kaifeng Wang, Baojun Ju, Xiangyu Wang, Guoming Pang

    Xuefu zhuyu Tang (XFZYT) is a classic formula used for promoting blood circulation and resolving blood stasis in Traditional Chinese Medicine. Clinical data have indicated that XFZYT plays a significant therapeutic role in diabetes-induced erectile dysfunction (DIED) disease, but the underlying mechanism remains elusive. Male Sprague–Dawley (SD) rats were randomly categorized into normal, model, and treatment groups. The diabetic rat model was established via intraperitoneal injection of streptozotocin. DIED rats were screened using apomorphine, and the number of erections was measured after 8 weeks of XFZYT treatment. Serum nitric oxide (NO) and endothelin-1 levels as well as penile tissue structure alterations were assessed by hematoxylin–eosin staining and electron microscopy. CaSR/PLC/PKC and MEK/ERK/RSK pathway-related proteins in the penile tissue were detected by western blotting (WB) analysis and polymerase chain reaction (PCR). Compared with the blank group, the model group rats showed a significant decrease in weight and erectile function. The pathological damage in the penile tissues of the model rats was indicated by a significantly decreased serum NO level and an increased endothelin-1 content. After treatment with XFZYT, the protein expression of CaSR, PLCβ1, PKCβ, MEK1, ERK1, and RSK1 in the penile tissue was significantly increased. Overall, the treatment group showed significant improvements in the evaluated indexes. In conclusion, this study revealed that XFZYT improves erectile function in diabetic rats, and the underlying mechanism might be linked with the regulation of CaSR/PLC/PKC and related molecules of the MEK/ERK/RSK pathway, which promotes the vascular endothelial diastolic effect.